Endogenous precursor messenger RNA in cardiomyocytes and smooth muscle cells (pre-mRNA (CMC/SMC))

Endogenous precursor messenger RNA (pre-mRNA) in cardiomyocytes and smooth muscle cells refers to the initial, unspliced transcripts of genes expressed within the muscular tissues of the heart and blood vessels. These molecules are essential intermediates in the central dogma, undergoing complex processing including 5' capping, polyadenylation, and splicing to form mature mRNA (Source: Nature Reviews Molecular Cell Biology, 2019). In the context of cardiovascular pathology, aberrant splicing or the presence of pathogenic mutations within these pre-mRNAs can lead to the production of dysfunctional proteins, contributing to conditions like dilated cardiomyopathy or vascular proliferative diseases (Source: Circulation, 2022). Therapeutic strategies targeting these pre-mRNAs primarily utilize antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs) to modulate gene expression or correct splicing defects (Source: Journal of Clinical Investigation, 2021). By binding to specific sequences, these drugs can either trigger RNase H-mediated degradation of the transcript or sterically block splicing factors to include or exclude specific exons (Source: Molecular Therapy, 2020). However, the clinical application of these therapies is currently limited by the difficulty of achieving high-efficiency, cell-specific delivery to cardiomyocytes and smooth muscle cells without systemic toxicity (Source: Advanced Drug Delivery Reviews, 2023).

Other names

Primary RNA transcriptsHeterogeneous nuclear RNAhnRNACardiac pre-mRNAVascular smooth muscle pre-mRNA

Therapeutic agents target these molecules through RNase H-mediated degradation of the transcript, splice-site modulation via steric hindrance of the spliceosome, or RNA interference pathways to alter protein production.